ARTH
Price
$0.23
Change
-$0.00 (-0.00%)
Updated
Dec 18 closing price
HRMY
Price
$33.50
Change
-$0.13 (-0.39%)
Updated
Dec 18, 04:59 PM (EDT)
62 days until earnings call
Ad is loading...

ARTH vs HRMY

Header iconARTH vs HRMY Comparison
Open Charts ARTH vs HRMYBanner chart's image
Arch Therapeutics
Price$0.23
Change-$0.00 (-0.00%)
Volume$4.38K
CapitalizationN/A
Harmony Biosciences Holdings
Price$33.50
Change-$0.13 (-0.39%)
Volume$5.74K
CapitalizationN/A
ARTH vs HRMY Comparison Chart
Loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTH vs. HRMY commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTH is a StrongBuy and HRMY is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (ARTH: $0.23 vs. HRMY: $33.48)
Brand notoriety: ARTH and HRMY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTH: 41% vs. HRMY: 71%
Market capitalization -- ARTH: $1.02M vs. HRMY: $1.91B
ARTH [@Biotechnology] is valued at $1.02M. HRMY’s [@Biotechnology] market capitalization is $1.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTH’s FA Score shows that 0 FA rating(s) are green whileHRMY’s FA Score has 0 green FA rating(s).

  • ARTH’s FA Score: 0 green, 5 red.
  • HRMY’s FA Score: 0 green, 5 red.
According to our system of comparison, HRMY is a better buy in the long-term than ARTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTH’s TA Score shows that 4 TA indicator(s) are bullish while HRMY’s TA Score has 3 bullish TA indicator(s).

  • ARTH’s TA Score: 4 bullish, 3 bearish.
  • HRMY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARTH is a better buy in the short-term than HRMY.

Price Growth

ARTH (@Biotechnology) experienced а +9.52% price change this week, while HRMY (@Biotechnology) price change was +3.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

ARTH is expected to report earnings on Aug 30, 2023.

HRMY is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HRMY($1.91B) has a higher market cap than ARTH($1.02M). HRMY YTD gains are higher at: 4.118 vs. ARTH (-96.823). HRMY has higher annual earnings (EBITDA): 218M vs. ARTH (-8.68M). HRMY has more cash in the bank: 410M vs. ARTH (30K). ARTH has less debt than HRMY: ARTH (9.39M) vs HRMY (183M). HRMY has higher revenues than ARTH: HRMY (682M) vs ARTH (148K).
ARTHHRMYARTH / HRMY
Capitalization1.02M1.91B0%
EBITDA-8.68M218M-4%
Gain YTD-96.8234.118-2,351%
P/E RatioN/A15.87-
Revenue148K682M0%
Total Cash30K410M0%
Total Debt9.39M183M5%
FUNDAMENTALS RATINGS
ARTH: Fundamental Ratings
ARTH
OUTLOOK RATING
1..100
1
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARTHHRMY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
ARTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDOGX13.230.01
+0.08%
Hennessy Total Return Investor
APDDX21.96-0.11
-0.50%
Artisan Global Discovery Advisor
CGRWX31.74-0.21
-0.66%
Invesco Comstock Select A
WFMDX48.98-0.45
-0.91%
Allspring Special Mid Cap Value Admin
MNDCX15.51-0.17
-1.08%
MFS New Discovery C

ARTH and

Correlation & Price change

A.I.dvisor tells us that ARTH and EDSA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARTH and EDSA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTH
1D Price
Change %
ARTH100%
+16.67%
EDSA - ARTH
21%
Poorly correlated
-1.58%
HRMY - ARTH
20%
Poorly correlated
+1.72%
BIVI - ARTH
13%
Poorly correlated
-1.97%
APLIF - ARTH
12%
Poorly correlated
N/A
BETRF - ARTH
5%
Poorly correlated
-10.11%
More

HRMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
+1.72%
SNBIF - HRMY
52%
Loosely correlated
N/A
SAGE - HRMY
39%
Loosely correlated
-1.40%
ANAB - HRMY
39%
Loosely correlated
-3.96%
RVNC - HRMY
39%
Loosely correlated
-0.65%
GYRE - HRMY
38%
Loosely correlated
+11.31%
More